HRMY Down 10.8% in Six Months: How Should You Play the Stock?

Shares of Harmony Biosciences (HRMY) have lost 10.8% in the past six months compared with the industry’s decline of 9.7%. The stock has also underperformed the S&P 500 index during this timeframe.The stock was hit last month after the company announced that it received a Refusal to File (RTF) letter from the FDA for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH).Image Source: Zacks Investment ResearchNonetheless, the fourth-quarter resul ...